Who
Myrtle S. Potter
Director
Company insider
Files Form 4 as: Director, Guardant Health; Director, Ginkgo Bioworks Holdings; Director, Myovant Sciences; Director, Urovant Sciences; Director, Immunovant; Director, Arbutus Biopharma; Director, Axsome Therapeutics; Director, Axovant Sciences.
In numbers
- Trades disclosed
- 233
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $2.7M
- Companies
- 16
- Companies where not an officer
- 16
- First trade
- 6 Jan 2006
- Last trade
- 22 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 23 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $204K1,556 at $131.16 | filing |
| 22 Jun 2026filed 23 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $204K1,556 at $131.16 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,711 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —2,711 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —4,203 at $0.00 | filing |
| 17 Oct 2025filed 20 Oct 2025 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $1,74126 at $66.95 | filing |
| 15 Oct 2025filed 16 Oct 2025 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —69 at $0.00 | filing |
| 15 Oct 2025filed 16 Oct 2025 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —69 at $0.00 | filing |
| 17 Sep 2025filed 17 Sep 2025 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $1,44626 at $55.63 | filing |
| 15 Sep 2025filed 17 Sep 2025 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —68 at $0.00 | filing |
| 15 Sep 2025filed 17 Sep 2025 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —68 at $0.00 | filing |
| 19 Aug 2025filed 20 Aug 2025 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $1,53526 at $59.02 | filing |
| 15 Aug 2025filed 18 Aug 2025 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —69 at $0.00 | filing |
| 15 Aug 2025filed 18 Aug 2025 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —69 at $0.00 | filing |
| 17 Jul 2025filed 18 Jul 2025 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Sold | $1,25326 at $48.20 | filing |
| 15 Jul 2025filed 16 Jul 2025 | GH Guardant Healthoption or derivative · Diagnostics & Labs | SEC FORM 4 Code M | —68 at $0.00 | filing |
| 15 Jul 2025filed 16 Jul 2025 | GH Guardant HealthDiagnostics & Labs | SEC FORM 4 Code M | —68 at $0.00 | filing |
News
Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?GH · insidermonkey.com · 20 Oct 2026Guardant Health (NASDAQ:GH) Director Sells $19,242.08 in StockGH · themarketsdaily.com · 19 Oct 2026Guardant Health (NASDAQ:GH) Stock Price Down 6.4% – Time to Sell?GH · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Myrtle S. Potter; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.